Phase II Study of S-1 plus Cisplatin as First-Line Therapy in Patients with Metastatic Esophageal Carcinoma

Abstract

Background: Patients with metastatic esophageal squamous cell cancer (ESCC) need safer and more efficacious treatments. The aim of this phase II study was to investigate the efficacy and safety of S-1 plus cisplatin as first-line therapy in metastatic ESCC. Patients and Methods: 50 patients with metastatic ESCC who had not received prior systemic chemotherapy for metastatic disease were enrolled. Patients received S-1 at 40 mg/m² divided into 2 daily doses for 14 days and cisplatin at 75 mg/m² on day 1 or 25 mg/m² on days 1-3 intravenously, repeated every 21 days with a maximum of 6 cycles. Results: 47 patients were assessable for response and 18 patients achieved a partial response, giving an overall response rate of 38.3%. Among those who had objective responses, a large percentage (72.2%) quickly showed remarkable tumor shrinkage during the first 2 cycles. 18 (38.3%) patients had stable disease. The median progression-free survival was 5.6 months, and the median overall survival was 12.0 months. Toxicity was mild to moderate and generally tolerable. Conclusion: The combination of S-1 plus cisplatin was a well-tolerated and convenient chemotherapy regimen with promising efficacy.

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

“…Patients with esophageal cancer commonly have advanced disease or metastases at diagnosis, and the current recommended standard first-line therapy for this advanced or metastatic disease is chemotherapy . However, the overall survival of patients receiving the standard of care, 2-drug cytotoxic agents, remains limited with a median of 7.0 to 13.0 months based on data from several prospective clinical studies . Therefore, novel drugs and strategies are required to improve clinical outcomes.…”

“…4 However, the overall survival of patients receiving the standard of care, 2-drug cytotoxic agents, remains limited with a median of 7.0 to 13.0 months based on data from several prospective clinical studies. [5][6][7] Therefore, novel drugs and strategies are required to improve clinical outcomes.…”

Economic evaluation of serplulimab plus chemotherapy as the first-line treatment of oesophageal squamous cell carcinoma in China

“…5 6 However, its efficacy and safety were unsatisfactory, with an overall survival (OS) of 7-13 months. [7][8][9] Consequently, there is a pressing need for improved treatment options to enhance the prognosis of patients with OC. In recent years, advances have been made in OC treatment, particularly the development of immunotherapy such as programmed cell death-ligand 1 (PD-L1)/PD-1 inhibitors.…”

“…For decades, platinum-based chemotherapy has stood as the primary first-line treatment for OC 5 6. However, its efficacy and safety were unsatisfactory, with an overall survival (OS) of 7–13 months 7–9. Consequently, there is a pressing need for improved treatment options to enhance the prognosis of patients with OC.…”